Calibr announces license agreement with Gilead to develop a long-acting HIV antiviral agent for treatment in combination with lenacapavir
LA JOLLA, CA — Calibr, the drug discovery and development division of Scripps Research, today announced Gilead Sciences, Inc. (Nasdaq: GILD) has exercised its option to exclusively license the research institute’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) prodrug. The NRTTI prodrug, designated GS-1614, is a development candidate resulting from a collaboration between Scripps Research and Gilead aimed at advancing a best-in-class long-acting HIV regimen.
Calibr ...








